Thymus neoplasm

Summary

Thymus neoplasm (MONDO:0005197) is a cancer and 16 clinical trials. Top therapeutic interventions include everolimus, plicamycin, and ribociclib. A subtype of endocrine gland neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thymus neoplasm
Mondo ID	MONDO:0005197
EFO	EFO:0002626
Orphanet	100100
NCIT	C3412
SNOMED CT	127231009
UMLS	C3714644
MedGen	811424
GARD	0019767
Anatomy (UBERON)	UBERON:0002370
Is cancer (heuristic)	yes

Also known as: neoplasm of the Thymus · neoplasm of Thymus · neoplasm of thymus · thymic neoplasm · thymic tumor · thymic tumour · THYMUS · Thymus neoplasm · thymus neoplasm (disease) · Thymus tumor · thymus tumor · Thymus tumour · thymus tumour · tumor of the Thymus · tumor of Thymus · tumor of thymus · tumour of the Thymus · tumour of Thymus · tumour of thymus

Data availability: 1 cell line.

Disease family

This is a subtype of endocrine gland neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › thymus neoplasm

Related subtypes (13): benign endocrine neoplasm, granulosa cell tumor, thyroid tumor, pituitary tumor, familial tumoral calcinosis, neuroendocrine neoplasm, malignant endocrine neoplasm, non-functioning endocrine neoplasm, functioning endocrine neoplasm, adrenal gland neoplasm, pineal body neoplasm, tumor of parathyroid gland, liver and intrahepatic bile duct neoplasm

Subtypes (4): thymus cancer, thymic epithelial neoplasm, thymic neuroendocrine tumor, benign neoplasm of thymus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cisplatin	Phase 3 (in late-stage trials)
Etoposide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Everolimus, Palbociclib, Prednisone, Ribociclib, Saracatinib, Selinexor, Sunitinib, Thymosin.

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	6
Not specified	6
PHASE1	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05918302	PHASE3	RECRUITING	Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
NCT05683886	PHASE2	RECRUITING	A Study of KC1036 in Patients with Advanced Thymic Tumors
NCT00990535	PHASE2	COMPLETED	High Dose Somatostatin Analogues in Neuroendocrine Tumors
NCT01610544	PHASE2	WITHDRAWN	18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
NCT01621568	PHASE2	COMPLETED	Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
NCT02364076	PHASE2	UNKNOWN	Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
NCT02420691	PHASE2	COMPLETED	Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
NCT02859415	PHASE1/PHASE2	TERMINATED	Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
NCT06885697	PHASE1	RECRUITING	Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
NCT00921739	PHASE1	COMPLETED	Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
NCT04822077	Not specified	RECRUITING	Study on Proton Radiotherapy of Thymic Malignancies
NCT06189183	Not specified	ACTIVE_NOT_RECRUITING	Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
NCT07072143	Not specified	RECRUITING	An International Study on Pediatric Patients With Rare Tumors.
NCT00591981	Not specified	COMPLETED	Thoracic OncoGeriatric Assessment (TOGA) Trials
NCT01851395	Not specified	TERMINATED	Rapid Autopsy and Procurement of Cancer Tissue
NCT03078699	Not specified	COMPLETED	Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EVEROLIMUS	4	1
PLICAMYCIN	4	1
RIBOCICLIB	4	1
EPACADOSTAT	3	1
CHEMBL451483	0	1